Abstract
Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100 000 patient years follow-up, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 × higher risk of subsequent MDS/AML compared to that seen in the general population. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aul C, Gattermann N and Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82: 358–367
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gahon DA, Gralnick HR and Sultan C (1982) FAB Cooperative Group. Proposals for the classification of myelodysplastic syndromes. Br J Haematol 51: 189–199
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick HR and Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 620–625
Bonadonna G, Valagussa P, Moliterni A, Zambetti M and Terenziani M (1993) Risk of acute leukemia and other malignances following CMF-based adjuvant chemotherapy for breast cancer. Proceedings of the American Society of Clinical Oncologists 12: 61
Bonadonna G, Valagussa P, Moliterni A, Zambetti M and Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901–906
Breslow NE and Day NE (1987) The design and analysis of cohort studies. In: Statistical methods in Cancer Research, citvol, 2. pp. 1–406, IARC Scientific Publications: Lyon
Brincker H, Rose C, Maase H and Dombernowsky P (1983) A randomized study of CAF-TAM (Tamoxifen) versus CMF + TAM in metastatic breast cancer. Proceedings of the American Society of Clinical Oncologists 3: 113
Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M and Hortobagyi GN (1996) Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas MD Anderson Cancer Center Experience. J Clin Oncol 14: 2722–2730
Ellis M, Ravid M and Lishner M (1993) A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma 11: 9–13
Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L and Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673–1682
Henderson IC, Garber JE, Breitmeyer JB and Hayesris JR (1990) Comprehensive management of disseminated breast cancer. Cancer 66: 1439–1448
Johansson B, Mertens F and Mitelman F (1996) Secondary neoplasia-associated chromosomal abnormalities-Balanced rearrangements vs genomic imbalances?. Genes Chromosomes Cancer 16: 155–163
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. American Statistical Association Journal 53: 457–481
Mitchell PL, Treleaven JG, Swansbury GJ, Powles RL, Ashley S and Powles T (1996) Secondary acute myeloid leukaemia (AML) and myelodysplasia (MDS) following mitoxantrone given as adjuvant therapy for breast cancer. Proceedings of the American Society of Clinical Oncologists 12: 127
Montes A, Powles TJ, O’Brien ME, Ashley SE, Luckit J and Treleaven J (1993) A toxic interaction betwen mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 29A: 1854–1857
Pedersen-Bjergaard J and Rowley J (1994) The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83: 2780–2786
Philpott NJ, Bevan DH and Gordon-Smith EC (1993) Secondary leukaemia after MMM combined modality therapy for breast carcinoma. Lancet 341: 1289
Powles TJ and Jones AL (1991) A randomised trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer 64: 406–410
Powles TJ, Hickish TF, Makris A, Ashley SE, O’Brien M, Tidy VA, Casey S, Nash A, Sacks N, Cosgrove D, MacVicar D, Fernando I and Ford HT (1995) Randomized trial of chemoendocrine therapy started before and after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–552
Rustin GJS, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foscett M, Fuller S and Short D (1996) Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 14: 2769–2773
Skuse GR and Ludlow JW (1995) Tumour suppressor genes in disease and therapy. Lancet 345: 902–906
Smith MA, McCaffrey RP and Karp JE (1996) The secondary leukemias: Challenges and research directions. J Natl Cancer Inst 88: 407–418
Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM and Wiernik PH (1995) Leukemogenic potential of adjuvant chemotherapy for early stage breast cancer: The Eastern Cooperative oncology group experience. J Clin Oncol 13: 1557–1563
Thirman MJ and Larson RA (1996) Therapy related myeloid leukemia. Hematol Oncol Clin North Am 10: 293–320
Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ and Oscier DG (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87: 743–745
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Saso, R., Kulkarni, S., Mitchell, P. et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83, 91–94 (2000). https://doi.org/10.1054/bjoc.2000.1196
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1196
Keywords
This article is cited by
-
Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer
Breast Cancer Research and Treatment (2022)
-
Expert perspectives on biosimilar monoclonal antibodies in breast cancer
Breast Cancer Research and Treatment (2014)
-
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation
Bone Marrow Transplantation (2012)
-
Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study
Breast Cancer (2012)
-
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients
Bone Marrow Transplantation (2003)